Ricci MS, Zong W-X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist. 2006;11(4):342-357.
Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67(19):8980-8984.
Joo WD, Visintin I, Mor G. Targeted cancer therapy—are the days of systemic chemotherapy numbered? Maturitas. 2013;76(4):308-314.
Jones TS, Holland EC. Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene. 2012;31(16):1995-2006.
Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-199.
Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiation Oncol Biol Phys. 979;5(1):85-91.
Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235-247.